CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

16-620 / S-045

ADMINISTRATIVE DOCUMENTS AND CORRESPONDENCE

16620

520

NDA 16-620/S-045
NDA 8-693/S-025
NDA 9-175/S-019

Mr. A.C. Ilse
Norwich Eaton Pharmaceuticals, Inc.
P.O. Box 191
Norwich, NY 13815

Dear Mr. Ilse:

Reference is made to your supplemental New Drug Applications (NDAs) dated January 14, 1988, submitted pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act for Furadantin^{R} (nitrofurantoin monohydrate) Oral Suspension, Furadantin Tablets, and Macrodantin.

We acknowledge receipt of twelve copies of the final printed labeling (FPL), and find them to be in accordance with our May 13, 1988 approval letter. They will be retained on file as the currently approved labeling for this product.

Sincerely yours,

Lillian Gavrilovich, M.D.
Acting Director
Division of Anti-Infective
Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

cc: NYK-DO
ORIG. NDA 16-620/S-045
ORIG. NDA 8-693/S-025
ORIG. NDA 9-175/S-019
HFD-82
HFD-220
HFD-520
HFD-521/CSO/JNazario/VFabritzky/11/28/88
HFD-520/MO/SAlpert
HFD-520/CHEM
HFD-520/PHARM
F/T: 11/30/88

ACKNOWLEDGED AND RETAINED 1646u

NORWICH EATON PHARMACEUTICALS, INC.

P.O. Box 191, Norwich, New York 13815

ORIG

SLR-045

Noted 8/2/88

July 12, 1988

Division of Anti-Infective Drug Products
Center for Drug Evaluation and Research (HFN-815)
Document Control Room 12B-30
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Re: NDA 16-620
Macrodantin®
(Nirofurantoin Macrocrystals)
Labeling Supplement S-045

Dear Dr. Tabor:

Enclosed are twelve (12) final copies of the Macrodantin package insert described in this supplement, which deals with pulmonary reactions associated with nitrofurantoin. The package insert implements the revision requested in your letter of May 13, 1988.

Sincerely,

A. C. Ilse
Regulatory Affairs
(607) 335-2572

Desk Copies:
Dr. Mercedes Albuerne, HFN-815, 12B-45
Mr. W. A. Brown, HFN-302, MPN-108

acim314/jvw

MAY 25 1988

NDA 8-693/S-025
NDA 9-175/S-019
[redacted]

Mr. A.C. Ilse
Norwich Eaton Pharmaceuticals, Inc.
P.O. Box 191
Norwich, NY 13815

Dear Mr. Ilse:

Reference is made to your supplemental New Drug Applications (NDAs) dated January 14, 1988, submitted pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act for Furadantin Tablets (NDA 8-693), Furadantin Oral Suspension (NDA 9-175), and Macrodantin (NDA 16-620).

Reference is also made to our letter of May 13,1988, and to your May 17, 1988 telephone conversation with Dr. M.S. Albuerne.

The following correction and modification should be made in the third sentence of the third paragraph on page 2 of the "Dear Doctor" letter:

[redacted]

This revision should be implemented and the "Dear Doctor" letter mailed within 15 days.

Sincerely yours,

Edward Tabor, M.D.
Director
Division of Anti-Infective
Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

cc:
ORIG. NDA 8-693/S-025
ORIG. NDA 9-175/S-019
ORIG. NDA 16-620/S-045
HFD-82
HFD-800/RNelson, Ph.D.
HFD-520 5/23/88
HFD-521/CBO/PDesantis/JNazario/sdj/5/19/88
HFD-520/MO/MSAlbuerne/5/18/88 MSA 5/23/88
HFD-520/PHARM
HFD-520/ERT/JEckert
HFD-366/Walter Brown/Regulatory Affairs
HFD-366/Dave Reed/Regulatory Affairs
F/D: 5/19/88
F/T: 5/19/88
1397n

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

Date JAN 22 1988

NDA No. 16-620

Norwich Eaton Pharmaceuticals, Inc.
P. O. Box 191
Norwich, New York 13815

Attention: A. C. Ilse

Dear Sir/Madam:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Macrodantin (Nitrofurantoin Macrocrystals)

NDA Number: 16-620

Supplement Number: S-045

Date of Supplement: 01-14-88

Date of Receipt: 01-21-88

All communications concerning this NDA should be addressed as follows:

Center for Drugs and Biologics, HFN-815
Attention: Document Control Room 12B-30
5600 Fishers Lane
Rockville, MD 20857

for Supervisory Consumer Safety Officer
Division of Anti-Infective Drug Products
Center for Drugs and Biologics

cc:
NDA File
HFN-815 File
CSO File

FORM FDA 3217d (7/84)

U.S. GOVERNMENT PRINTING OFFICE-1984-450-521/7435

21.1

NORWICH EATON PHARMACEUTICALS, INC.

P.O. Box 191, Norwich, New York 13815

January 14, 1988

Division of Anti-Infective Drug Products
Center for Drug Evaluation and Research (HFN-815)
Document Control Room 12B-30
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

NDA NO. 16-620 REF. NO. 5045
NDA SUPPL FOR LR

Re: NDA #16-620
Macrodantin®
(Nitrofurantoin Macrocrystals)
Labeling Supplement

Dear Dr. Tabor:

This labeling supplement for Macrodantin® provides for package insert modifications of the information dealing with pulmonary reactions associated with nitrofurantoin. In addition, an information letter for physicians is also provided.

These items were the basis of a discussion between representatives of Norwich Eaton Pharmaceuticals, Inc. and the Agency on January 5, 1988. The package insert reflects our understanding of the labeling agreed upon at that meeting. The physician information letter has been modified as requested, and minor editorial changes have also been made.

In an effort to aid in physician awareness of pulmonary reactions to nitrofurantoin, we are revising the "Warnings", "Adverse Reaction", and "Dosage and Administration" sections of the package insert. In the "Warnings" section the pulmonary reactions will be highlighted by bold face type. In addition the wording has been revised to emphasize the temporal relationship of the chronic pulmonary reaction with therapy of 6 months or longer. The "Adverse Reactions" section has been revised to lead off with pulmonary reactions, and the text dealing with the chronic reaction is in bold face type. As in the "Warnings", the wording has been revised to emphasize the temporal relationship of the chronic reaction with therapy of 6 months or longer. The "Dosage and Administration" section text on long term therapy will also be highlighted in bold face type.

In addition to the labeling changes outlined above, we intend to send physicians a letter providing information on the nature of the pulmonary reactions associated with nitrofurantoin and alerting them to our package insert changes. This letter will be sent out to all urologists, OB-GYN's, family practitioners, internal medicine specialists, general practitioners, pediatricians, osteopathic physicians, general surgeons, and pulmonary disease specialists. In all this will include over 200,000 physicians, who comprise over 99% of the physicians who prescribe nitrofurantoin.

We also intend to have our sales representatives follow up with each of their physicians to insure that they have received this letter and understand its

content. We will be providing our representatives with extra copies of this letter to provide to physicians who do not remember receiving it.

Included in this supplement you will find copies of the draft package insert, the information letter, and a bibliography of the scientific literature which discusses the pulmonary reactions.

We are also submitting similar supplements to the NDA's for Furadantin Tablets, and Oral Suspension.

Sincerely,

A. C. Ilse
Regulatory Affairs
(607) 335-2572

Desk Copies:
Dr. Mercedes Albuerne, HFN-815, 12B-45
Dr. Edward Tabor, HFN-815, 12B-45

acim255/jvw
Enc.